# Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT02514382** · PHASE1 · COMPLETED · sponsor: **University of Southern California** · enrollment: 14 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **BIOLOGICAL:** Wild-type Reovirus

## Key facts

- **NCT ID:** NCT02514382
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-21
- **Primary completion:** 2022-04-19
- **Final completion:** 2022-04-19
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-08-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02514382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02514382, "Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02514382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*